A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3047-3055

  Carducci, Michael A ^a,a   Gilbert, Jill ^a   Bowling, M Katherine ^a   Eisenberger, Mario A ^a   Sinibaldi, Victoria ^a   Grochow, Louise B ^a   Donehower, Ross C ^a   Noe, Dennis ^a   Zabelina, Yelena ^a   Chen, Tian Ling ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; DRUG METABOLITE; PHENYLACETIC ACID; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INFUSION; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; MALE; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; SOMNOLENCE;

ADULT; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; GLUTAMINE; HUMANS; HYPOKALEMIA; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NAUSEA; NEOPLASMS; NEUTROPENIA; PATIENT DROPOUTS; PHENYLACETATES; PHENYLBUTYRATES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED; URIC ACID;

EID: 0034796871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Induced cell differentiation in cancer therapy
2. Differentiation agents yield treatment, prevention options
3. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
4. Retinoids, interferon α, 1, 25-dihydroxyvitamin D3 and their combination inhibit angiogenesis, induced by non-HPV-harboring tumor cell lines. RAR α mediates the antiangiogenic effect of retinoids
5. Prostate cancer treatment strategies based on tumor-specific biological principles: Future directions
6. Prolonged infusion of hexamethylene bisacetamide: A phase I and pharmacological study
7. Phase I and pharmacological study of hexamethylene bisacetamide in patients with advanced cancer
8. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
9. Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities
10. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
11. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation
12. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
13. Vulnerability of multi-drug resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate
14. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate
15. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines
16. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration, and invasiveness of malignant glioma cells
17. Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria
18. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-thalassemia
19. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion
20. Restoration of nitrogen hemostasis in a man with ornithine transcarbamylase deficiency
21. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis
22. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: Review of nine cases
23. Transcriptional upregulation of TGF-α by phenylacetate and phenylbuytrate is associated with differentiation of human melanoma cells
24. Transcriptional upregulation of γ globin by phenylbutyrate and analogous aromatic fatty acids
25. Phenylbutyrate has pleiotropic effects on gene transcription and inhibits telomerase activity inhuman prostate cancer
26. Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines
27. Activation of human peroxisome proliferator activator receptor by the antitumor agent phenylacetate and its analogs
28. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylase
29. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation, and histone deacetylase
30. Induced differentiation, the cell cycle, and the treatment of cancer
31. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
32. Mini mental state," a practical method for grading the cognitive state of patients for the clinician
33. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells
34. Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia
35. Differentiation therapy in acute myeloid leukemia
36. Prevention of secondary primary tumors with isotretinoin in squamous cell carcinoma of the head and neck
37. Intefferon-α-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in phase II trial and interactions in vitro
38. Inducing differentiation of transformed cells with hybrid polar compounds: A cell cycle-dependent process
39. Vitamin D and Prostate Cancer: 1, 25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
40. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
41. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine
42. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
43. Actions of vitamin D3 analogs on human prostate cancer cell lines: Comparison with 1, 25-dihydroxyvitamin D3
44. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells
45. Control of LnCAP proliferation and differentiation: Actions and interactions of androgens, 1 α, 25-dihydroxycholecalciferol, all-transretinoic acid, 9-cis-retinoic acid, and phenylacetate
46. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis
47. The nuclear receptors PPARS as novel targets in differentiation therapy: Activation by phenylacetate and phenylbutyrate
48. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer